Jay Yang

The Barbara Ann Karmanos Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study”.

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4929

N/A

0.953DataRank · unranked

25 citations

Husain Yar Khan, Yiwei Li, Mahmoud Chaker, Irfana Muqbil, Amro Aboukameel +18 more

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

Leukemia(2021)10.1038/s41375-021-01328-9

N/A

0.783DataRank · unranked

184 citations

Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji +35 more

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

Haematologica(2020)10.3324/haematol.2019.233445

N/A

0.598DataRank · unranked

53 citations

Yongwei Su, Katie Hege, Gerard J. Madlambayan, Holly Edwards, Tristan Knight +13 more

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro

Biochemical Pharmacology(2023)10.1016/j.bcp.2023.115981

N/A

0.442DataRank · unranked

18 citations

Yongwei Su, Shraddha Patel, Cassandra L. Ramage, Jianlei Zhao, Brianna R. Temby +24 more

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and purine biosynthesis

Research Square(2023)10.21203/rs.3.rs-2843025/v1

N/A

0.165DataRank · unranked

2 citations

Katie Hege-Hurrish, Yongwei Su, Shraddha Patel, Cassandra L. Ramage, Jenna L. Carter +22 more

Dynamic changes to signal allocation rules in response to variable social environments in house mice

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.01.28.478242

N/A

0DataRank · unranked

6 citations

Matthew F. Hillock, Jay Yang, Brandon Carlson-Clarke, Klaudio Haxhillari, Annie Y. Lee +3 more

Omega-3/Omega-6 Long-Chain Fatty Acid Imbalance in Phase I Retinopathy of Prematurity

Nutrients(2022)10.3390/nu14071333

N/A

0DataRank · unranked

31 citations

Wenjun Yan, Chuck T. Chen, Anders Nilsson, Edward Bull, William E. Allen +8 more

Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms

Biochemical Pharmacology(2023)10.1016/j.bcp.2023.115759

N/A

0DataRank · unranked

17 citations

Yongwei Su, Xinan Qiao, Jianlei Zhao, Guan Wang, MacKenzie A. Howard +8 more

FGF21 via mitochondrial lipid oxidation promotes physiological vascularization in a mouse model of Phase I ROP

Angiogenesis(2023)10.1007/s10456-023-09872-x

N/A

0DataRank · unranked

15 citations

Pia Lundgren, Aldina Pivodic, Hitomi Yagi, Jarrod C. Harman, Jay Yang +6 more

Postnatal hyperglycemia alters amino acid profile in retinas (model of Phase I ROP)

iScience(2023)10.1016/j.isci.2023.108021

N/A

0DataRank · unranked

6 citations

Aldina Pivodic, Anders Nilsson, Myriam Boeck, Hitomi Yagi, Katherine Neilsen +6 more

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Blood(2023)10.1182/blood-2023-187861

N/A

0DataRank · unranked

5 citations

Joseph G. Jurcic, Maria R. Baer, William Blum, P. Brent Ferrell, Brian A. Jonas +7 more

Cytochrome P450 oxidase 2J inhibition suppresses choroidal neovascularization in mice

Metabolism(2022)10.1016/j.metabol.2022.155266

N/A

0DataRank · unranked

10 citations

Yohei Tomita, Matthew L. Edin, Anli Ren, Minji Ko, Jay Yang +6 more

Inhibition of CDK 9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology(2025)10.1002/1878-0261.70124

N/A

0DataRank · unranked

0 citations

Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu +14 more